TrialSignal
Clinical trial intelligence report
Are We Overly Concerned About Rebound Fractures? Real-World Evidence of Adherence to Denosumab Therapy and Fracture Risk Associated With Drug Withdrawal: A Cross-sectional Study
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT06414616
Status
COMPLETED
Phase
Observational
Sponsor
Trakya University
Executive brief
Investment-Ready Snapshot
This study investigates the adherence to Denosumab therapy and the associated fracture risk upon discontinuation, particularly during the COVID-19 pandemic. It aims to provide real-world evidence on the implications of treatment compliance and the potential rebound effect on fracture risk in osteoporosis patients.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT06414616
Indication
Osteoporosis
Modality
monoclonal antibody
Target
Osteoporosis
Intervention
Not reported
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.